JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snitkovsky, S.
Right arrow Articles by Young, J. A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snitkovsky, S.
Right arrow Articles by Young, J. A. T.

 Previous Article  |  Next Article 

Journal of Virology, February 2001, p. 1571-1575, Vol. 75, No. 3
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.3.1571-1575.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Targeting Avian Leukosis Virus Subgroup A Vectors by Using a TVA-VEGF Bridge Protein

Sophie Snitkovsky,1,2 Thomas M. J. Niederman,3 Richard C. Mulligan,3 and John A. T. Young2,4,*

Committee on Virology1 and Department of Microbiology and Molecular Genetics,2 Harvard Medical School, and Howard Hughes Medical Institute at The Children's Hospital,3 Boston, Massachusetts 02115, and Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin---Madison, Madison, Wisconsin 537064

Received 31 July 2000/Accepted 8 November 2000

Previously, we have demonstrated that bridge proteins comprised of avian leukosis virus (ALV) receptors fused to epidermal growth factor (EGF) can be used to selectively target retroviral vectors with ALV envelope proteins to cells expressing EGF receptors. To determine whether another type of ligand incorporated into an ALV receptor-containing bridge protein can also function to target retroviral infection, the TVA-VEGF110 bridge protein was generated. TVA-VEGF110 consists of the extracellular domain of the TVA receptor for ALV subgroup A (ALV-A), fused via a proline-rich linker peptide to a 110-amino-acid form of vascular endothelial growth factor (VEGF). This bridge protein bound specifically to its cell surface receptor, VEGFR-2, and efficiently mediated the entry of an ALV-A vector into cells. These studies indicate that ALV receptor-ligand bridge proteins may be generally useful tools for retroviral targeting approaches.

* Corresponding author. Mailing address: McArdle Laboratory for Cancer Research, University of Wisconsin at Madison, 1400 University Ave., Madison, WI 53706. Phone: (608) 265-5151. Fax: (608) 262-2824. E-mail: young{at}oncology.wisc.edu.

Journal of Virology, February 2001, p. 1571-1575, Vol. 75, No. 3
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.3.1571-1575.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.